CEO Sean Bohen received total compensation of approximately $3.18 million in 2025, which is reasonable for a biotech CEO at a $1.2 billion company and is well within expected benchmarks for the title, sector, and market cap band. The pay structure is appropriately weighted toward variable compensation — salary of $699,920 represents about 22% of total pay, with the remainder in performance-based bonus and stock options that vest over time, satisfying the policy requirement that fixed pay not exceed 40% of total compensation. The company received over 95% shareholder support on Say on Pay at the 2025 annual meeting, reflecting broad shareholder endorsement, and OLMA's stock has dramatically outperformed both its peers and the XBI — SPDR S&P Biotech ETF benchmark over the past three years, confirming that incentive pay is well-aligned with shareholder outcomes. The company also has a compliant clawback policy in place per Nasdaq Listing Standard 5608.

Ernst & Young has audited Olema since 2020, giving it approximately 6 years of tenure — well below the 25-year threshold that would raise independence concerns. Non-audit fees (tax services of $314,794) represent about 51% of audit fees ($621,000), which is just above the 50% threshold; however, this is driven entirely by routine tax compliance and R&D tax incentive work with no consulting or advisory overlap, and the company is a $1.2B market cap biotech appropriately served by a Big 4 firm. On balance, the ratio is at the margin and the nature of the fees does not indicate a compromised independence relationship, so a FOR vote is appropriate.